My Lung Cancer has recurred. How does this change my treatment choices, and are new targeted therapies using...

According to the NCCN Guidelines for Non-Small Cell Lung Cancer (2023), when cancer recurs, treatment options depend heavily on several factors:

1. Biomarker Testing: The NCCN strongly recommends comprehensive biomarker testing for all recurrent lung cancers, specifically looking for:

• EGFR mutations
• ALK rearrangements
• PD-L1 expression
• ROS1, BRAF, NTRK, MET, RET, and other actionable mutations

1. Treatment Options: According to ASCO Guidelines (2023), treatment choices for recurrent lung cancer may include:

• Targeted therapies if specific mutations are found
• Immunotherapy (especially if high PD-L1 expression)
• Chemotherapy
• Clinical trials
• Local treatments (radiation/surgery) for isolated recurrences

The National Cancer Institute (NCI) emphasizes that newer targeted therapies have shown impressive results in treating recurrent lung cancer, particularly:

• Osimertinib for EGFR mutations
• Alectinib or brigatinib for ALK-positive cancers
• Pembrolizumab or other immunotherapy drugs for high PD-L1 expression

Important recommendations:

1. Discuss comprehensive biomarker testing with your oncologist
2. Ask about the latest FDA-approved targeted therapies for your specific mutation type
3. Consider clinical trial opportunities

Remember, this information is general guidance. Your specific treatment plan should be determined by your healthcare team based on your individual case, including the location of recurrence, previous treatments, and biomarker status.